trial summary · NCT07748611
SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial
SMART-PANC: SMAD4 Tailored Neoadjuvant Therapy for Pancreatic Cancer, A Phase ll Non-Randomized, Single Center Pilot Study
Trial record from the TrialBase DB dataset, status RECRUITING, condition Borderline Resectable Pancreatic Ductal Adenocarcinoma, sponsored by Northwestern University. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
This phase II trial tests the impact of using SMAD4-mutant status to personalize chemotherapy in treating patients with pancreatic ductal adenocarcinoma (PDAC) that can be removed by surgery (resectable) or that may be between resectable and unresectable (borderline resectable) before undergoing surgery (neoadjuvant). PDAC is one of the most aggressive and fastest growing tumors. SMAD4, a tumor suppressor gene, acts like a brake on cell growth and helps to prevent tumor cells from growing. However, losing it makes the tumor more aggressive and often resistant to standard of care (SOC) treatments regimens, such as gemcitabine with nab-paclitaxel and fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX). Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic (DNA) and may kill tumor cells. Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of paclitaxel which may have fewer side effects and work better than other forms of paclitaxel. Fluorouracil, a type of antimetabolite, stops cells from making DNA and it may kill tumor cells. Leucovorin is a form of folic acid. It is a type of chemoprotective agent and a type of chemosensitizing agent. Irinotecan is in a class of antineoplastic medications called topoisomerase I inhibitors. It blocks a certain enzyme needed for cell division and DNA repair and may kill tumor cells. Oxaliplatin is in a class of medications called …
Source record: https://clinicaltrials.gov/study/NCT07748611
Facts
| registry id | NCT07748611 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE2 |
| study type | INTERVENTIONAL |
| lead condition | Borderline Resectable Pancreatic Ductal Adenocarcinoma |
| sponsor | Northwestern University |
| sponsor class | OTHER |
| enrollment | 125 |
| start date | 2026-10-26 |
| primary completion | 2030-02-03 |
| completion | 2031-02-03 |
| results posted | not reported |
Conditions
- Borderline Resectable Pancreatic Ductal Adenocarcinoma
- Resectable Pancreatic Ductal Adenocarcinoma
Interventions
- Biospecimen Collection
- Computed Tomography
- Electronic Health Record Review
- Fluorouracil
- Gemcitabine
- Irinotecan
- Leucovorin
- Magnetic Resonance Imaging
- Nab-paclitaxel
- Oxaliplatin
- Radiation Therapy
- Surgical Procedure
Countries
- United States
Intervention types: DRUG, OTHER, PROCEDURE, RADIATION
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.